GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syngene International Ltd (BOM:539268) » Definitions » Debt-to-EBITDA

Syngene International (BOM:539268) Debt-to-EBITDA : 0.42 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Syngene International Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Syngene International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹901 Mil. Syngene International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹4,651 Mil. Syngene International's annualized EBITDA for the quarter that ended in Mar. 2024 was ₹13,320 Mil. Syngene International's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.42.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Syngene International's Debt-to-EBITDA or its related term are showing as below:

BOM:539268' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.51   Med: 1.21   Max: 2.35
Current: 0.51

During the past 13 years, the highest Debt-to-EBITDA Ratio of Syngene International was 2.35. The lowest was 0.51. And the median was 1.21.

BOM:539268's Debt-to-EBITDA is ranked better than
68.5% of 273 companies
in the Biotechnology industry
Industry Median: 1.3 vs BOM:539268: 0.51

Syngene International Debt-to-EBITDA Historical Data

The historical data trend for Syngene International's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syngene International Debt-to-EBITDA Chart

Syngene International Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 1.16 1.26 0.81 0.51

Syngene International Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 - 0.78 - 0.42

Competitive Comparison of Syngene International's Debt-to-EBITDA

For the Biotechnology subindustry, Syngene International's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syngene International's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syngene International's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Syngene International's Debt-to-EBITDA falls into.



Syngene International Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Syngene International's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(901 + 4651) / 10939
=0.51

Syngene International's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(901 + 4651) / 13320
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Syngene International  (BOM:539268) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Syngene International Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Syngene International's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Syngene International (BOM:539268) Business Description

Traded in Other Exchanges
Address
Jigani Link Road, Biocon SEZ, Biocon Park, Plot No. 2 and 3, IV Phase, Bommasandra Industrial Area, Bangalore, KA, IND, 560 099
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the US. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.

Syngene International (BOM:539268) Headlines

No Headlines